Publication

Semi-Mechanistic Joint Population Pharmacokinetic Modeling of the Novel Antituberculosis Drug Sorfequiline and Its Metabolite M3 in Healthy Volunteers

A semi-mechanistic population PK model characterizes sorfequiline and its active M3 metabolite to support DDI…

CertaraSeptember 18, 2026

Poster

Pharmacometric Analysis of Givinostat to Support Individualized Dosing Recommendations in Pediatric Patients with Duchenne Muscular Dystrophy

Pharmacometric modeling of givinostat in pediatric DMD supported a simplified 4-band weight-based dosing regimen without…

CertaraSeptember 14, 2026

Guide

From Models to Decisions: Building MIDD Readiness in the Era of ICH M15

Explore what ICH M15 means for Model-Informed Drug Development and learn how to build MIDD…

Rik de GreefSeptember 9, 2026

On-Demand Webinar

From Sentence to Simulation: Bringing AI Assistance to Pharmacometrics Modeling

Describe pharmacometric models in natural language and let AI write ready-to-run NLME code. See the…

Arjen BosSeptember 1, 2026

Live Events

An Introduction to Fast and Reliable Modeling with RsNLME and Agentic AI

CertaraSeptember 1, 2026

Publication

A glimpse into the future of model-informed drug discovery and development

Explore the future of Model-Informed Drug Development (MIDD), including advances in pharmacometrics, PBPK, QSP, precision…

CertaraAugust 28, 2026

Publication

Refinement of Operating Characteristics for Model-Based TGI Metrics Decision Support to Ungate a Pivotal Trial in Oncology

Explore how model-based tumor growth inhibition metrics can support earlier Go/No-Go decisions and pivotal trial…

CertaraAugust 28, 2026

Blog

Why pharmacometrics automation is the foundation of modern PK/PD

Pharmacometrics automation is reshaping PK/PD workflows. Explore five principles driving AI, cloud infrastructure, and model…

Sebastian KuechenmeisterAugust 28, 2026

Blog

The five drug development questions that bring sponsors to pharmacometrics

Sponsors rarely come to pharmacometrics because they need a model. They come with a development…

Rik de GreefAugust 24, 2026

Blog

A model-informed approach to radioligand therapy dosing under Project Optimus

Explore how targeted radionuclide therapy dosing uses QSP, biologically effective dose (BED), and exposure-response modeling…

Hunter Stephens, PhDAugust 13, 2026

Clinical Pharmacology

Semi-Mechanistic Joint Population Pharmacokinetic Modeling of the Novel Antituberculosis Drug Sorfequiline and Its Metabolite M3 in Healthy Volunteers

Pharmacometric Analysis of Givinostat to Support Individualized Dosing Recommendations in Pediatric Patients with Duchenne Muscular Dystrophy

From Models to Decisions: Building MIDD Readiness in the Era of ICH M15

From Sentence to Simulation: Bringing AI Assistance to Pharmacometrics Modeling

An Introduction to Fast and Reliable Modeling with RsNLME and Agentic AI

A glimpse into the future of model-informed drug discovery and development

Refinement of Operating Characteristics for Model-Based TGI Metrics Decision Support to Ungate a Pivotal Trial in Oncology

Why pharmacometrics automation is the foundation of modern PK/PD

The five drug development questions that bring sponsors to pharmacometrics

A model-informed approach to radioligand therapy dosing under Project Optimus

Newsletter sign up

Quick links

Solutions

Contact